In a China cohort study [72], a lower frequency of JAK2 V617F mutation was found in Chinese patients with BCS, suggesting that the major cause of BCS in this population might not be MPN, whereas the JAK2 V617F mutation indicated a higher prevalence in non-cirrhotic and non-malignant PVT patients (p < 0.001). This evidence concerns the gene JAK2 and myeloproliferative disorder.